{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:53:14Z","timestamp":1772643194367,"version":"3.50.1"},"reference-count":17,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.2217\/imt-2019-0027","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T07:54:06Z","timestamp":1567065246000},"page":"1187-1192","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Bullous pemphigoid associated with the 480-mg nivolumab dose in a patient with metastatic renal cell carcinoma"],"prefix":"10.1080","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9577-8517","authenticated-orcid":false,"given":"Amruth Ratnakar","family":"Palla","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, Department of Internal Medicine, Ellis Fischel Cancer Center, University of MissouriColumbia, MO65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Missouri, Columbia, MO65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Doll","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Internal Medicine, Ellis Fischel Cancer Center, University of MissouriColumbia, MO65212, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Food and Drug Administration (FDA) . https:\/\/www.drugs.com\/newdrugs\/bristol-myers-squibb-s-opdivo-nivolumab-now-firstonly-fda-approved-pd-1-inhibitor-offer-every-four-4707.html"},{"key":"e_1_3_4_3_1","unstructured":"SEER. National Cancer Institute . https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.002"},{"key":"e_1_3_4_5_1","unstructured":"Food and Drug Administration (FDA). https:\/\/www.drugs.com\/newdrugs\/fda-approves-opdivo-metastatic-renal-cell-carcinoma4302.html"},{"key":"e_1_3_4_6_1","unstructured":"Food and Drug Administration (FDA). https:\/\/www.drugs.com\/newdrugs\/afinitor-approved-us-first-patients-advanced-kidneycancer-after-failure-either-sunitinib-sorafenib-1305.html"},{"key":"e_1_3_4_7_1","unstructured":"Food and Drug Administration (FDA). https:\/\/www.drugs.com\/newdrugs\/fda-approves-inlyta-advanced-renal-cell-carcinoma3072.html"},{"key":"e_1_3_4_8_1","unstructured":"Food and Drug Administration (FDA). https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm520871.htm"},{"key":"e_1_3_4_9_1","unstructured":"National Comprehensive Cancer Network . https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8633-4"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.05.009"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14143"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0128"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0123"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/68289"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12378"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0091"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13970"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2019-0027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:55:24Z","timestamp":1715972124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2019-0027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.2217\/imt-2019-0027"],"URL":"https:\/\/doi.org\/10.2217\/imt-2019-0027","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}